Aaron J. Peoples, Somerville, MA (US); Dallas Hughes, Bolton, MA (US); Losee Lucy Ling, Arlington, MA (US); William Millett, Worcester, MA (US); Anthony Nitti, Lexington, MA (US); Amy Spoering, Waltham, MA (US); Victoria Alexandra Steadman, Ongar (GB); Jean-Yves Christophe Chiva, Ongar (GB); Linos Lazarides, Ongar (GB); Michael Kenyon Jones, Ongar (GB); Karine Gaelle Poullennec, Ongar (GB); Kim Lewis, Newton, MA (US); and Slava Epstein, Dedham, MA (US)
Assigned to NovoBiotic Pharmaceuticals, LLC, Cambridge, MA (US)
Filed by NovoBiotic Pharmaceuticals, LLC, Cambridge, MA (US)
Filed on Oct. 13, 2021, as Appl. No. 17/500,761.
Application 17/500,761 is a continuation of application No. 16/529,342, filed on Aug. 1, 2019, granted, now 11,174,290.
Application 16/529,342 is a continuation of application No. 15/183,031, filed on Jun. 15, 2016, granted, now 10,414,800, issued on Sep. 17, 2019.
Application 15/183,031 is a continuation of application No. 14/789,819, filed on Jul. 1, 2015, granted, now 9,402,878, issued on Aug. 2, 2016.
Application 14/789,819 is a continuation of application No. 14/095,415, filed on Dec. 3, 2013, granted, now 9,163,065, issued on Oct. 20, 2015.
Claims priority of provisional application 61/732,894, filed on Dec. 3, 2012.
Prior Publication US 2022/0289793 A1, Sep. 15, 2022
1. A method of treating a bacterial infection in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a compound of Formula (II), or a tautomer or a pharmaceutically-acceptable salt thereof, and a pharmaceutically acceptable carrier; wherein the compound of Formula (II) is:
